ReviewImmunity & ageing : I & A2025
CD8⁺ T cell heterogeneity in aging: insights from single-cell profiling.
Review in Immunity & ageing : I & A, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of CD8Frontiers in immunology · 2026Pooled it
- Article
- CD4/CD8 ratio is associated with structural reorganization of vaccine-induced immune responses in people living with HIV.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Inflammation progressively increases with age, resulting in a broad remodeling of the CD8⁺ T cell compartment. Recent advances in single-cell RNA sequencing (scRNA-seq) have revealed a transcriptional heterogeneity within the CD8⁺ T cell subsets, challenging traditional classifications based on surface markers. This review summarizes current insights from scRNA-seq and multimodal profiling studies, demonstrating a heterogeneity of CD8⁺ T cell states defined by distinct and overlapping transcriptional programs. Notably, GZMK⁺ effector memory T cells expand with age, and recent studies in mouse models suggest that GZMK⁺ T cells can activate the complement system, positioning them as potential mediators of inflammation. In addition, emerging diversity within TEMRA and non-canonical T cell subsets challenges the conventional boundaries between established T cell subsets. Integrative single-cell approaches are essential for deciphering the dynamic interplay between immune aging and chronic disease, and for informing targeted interventions to restore immune resilience in older adults.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.